Genetic testing

Global Reproductive Genetics Market (2020 to 2030) - Focus on Procedure Type, Product Type, Technology, Application Type and Country Data - ResearchAndMarkets.com

Friday, June 11, 2021 - 3:22pm

The "Global Reproductive Genetics Market: Focus on Procedure Type, Product Type, Technology, Application Type, Country Data (15 countries) - Analysis and Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Reproductive Genetics Market: Focus on Procedure Type, Product Type, Technology, Application Type, Country Data (15 countries) - Analysis and Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
  • Reproductive genetics is a branch of science that contributes to predicting and preventing a genetic disorder during the reproductive procedure (both natural and artificial).
  • There has been steady progress in the demand for various methods of reproductive genetic testing.
  • Within the research report, the market has been segmented on the basis of procedure type, product type, application type, technology, and region.

Genetic Health Information Network Summit Will Address Data and Digital Infrastructure for Precision Medicine

Thursday, June 10, 2021 - 4:00pm

NASHVILLE, Tenn., June 10, 2021 /PRNewswire/ -- Concert Genetics, in collaboration with leaders from across genetics and healthcare, today announced the 4th Genetic Health Information Network Summit will take place October 25-27, 2021, in Nashville, Tenn.

Key Points: 
  • NASHVILLE, Tenn., June 10, 2021 /PRNewswire/ -- Concert Genetics, in collaboration with leaders from across genetics and healthcare, today announced the 4th Genetic Health Information Network Summit will take place October 25-27, 2021, in Nashville, Tenn.
  • This event assembles leaders at the intersection of genetics, technology, and healthcare, to solve the data and digital infrastructure challenges in precision medicine.
  • "We look forward to bringing this group back together to accelerate that advancement in the hopes of establishing a truly connected health information network to power precision medicine."
  • Concert's genetic testing management capabilities leverage a proprietary database of the U.S. clinical genetic testing market, market-leading expertise, and a technology platform that supports genetic test ordering, resulting, coding, coverage, and payment integrity.

Entheon Biomedical's Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit Now Available for Sale in US

Thursday, June 10, 2021 - 1:30pm

HaluGen Life Sciences' test evaluates an individual's overall sensitivity and risk profile associated with psychedelic-assisted therapy

Key Points: 
  • The Psychedelics Genetic Test Kit, a first of its kind, was designed and commercialized by HaluGen, and launched in Canada on April 5, 2021.
  • The Psychedelics Genetic Test Kit provides users with personalized reports and actionable insights, delivered directly to one's smartphone or desktop through the HaluGen website customer platform, providing a convenient and safe means to better understand one's sensitivity to psychedelics and ketamine.
  • The test also provides insights into the short and long-term potential of psychedelic-induced risks, such as psychosis.
  • Psychedelics Genetic Test Kit customers receive a swab kit that is shipped directly to their home and the unique kit identifier is registered on HaluGen's secure online portal.

Concert Genetics Earns Patent for Innovative Methods of Automating Genetic Test Coverage and Payment Accuracy

Wednesday, June 9, 2021 - 4:00pm

NASHVILLE, Tenn., June 9, 2021 /PRNewswire/ -- The U.S. Patent and Trademark Office has issued Concert Genetics patent US10,896,405B1 for innovative methods that enable real-time coverage determination and accurate reimbursement of genetic tests, the company announced today.

Key Points: 
  • NASHVILLE, Tenn., June 9, 2021 /PRNewswire/ -- The U.S. Patent and Trademark Office has issued Concert Genetics patent US10,896,405B1 for innovative methods that enable real-time coverage determination and accurate reimbursement of genetic tests, the company announced today.
  • This system leverages Concert's platform for collecting, standardizing and organizing genetic test information, represented in patent US10,223,501B1 .
  • By improving the speed and accuracy of coverage and payment decisions, the capability ultimately shortens the patient's path to clinically appropriate testing.
  • "Today, confusion about genetic test coverage and reimbursement leads to burdensome, manual processes that waste time and deliver inconsistent results.

Myriad Genetics CEO Paul J. Diaz to Present at Goldman Sachs 2021 Virtual Global Healthcare Conference

Friday, June 4, 2021 - 12:05pm

SALT LAKE CITY, June 04, 2021 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will discuss the companys transformation plan and growth initiatives during a fireside chat at the Goldman Sachs 2021 Virtual Global Healthcare Conference at 8:50 a.m. EST on June 10, 2021.

Key Points: 
  • SALT LAKE CITY, June 04, 2021 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will discuss the companys transformation plan and growth initiatives during a fireside chat at the Goldman Sachs 2021 Virtual Global Healthcare Conference at 8:50 a.m. EST on June 10, 2021.
  • Diaz will be joined by Bryan Riggsbee, chief financial officer of Myriad Genetics.
  • The presentation will be available via a live audio webcast accessible through the investor section of the Myriad Genetics website at www.myriad.com .
  • Myriad Genetics Inc. is a leading genetic testing and precision medicine company dedicated to advancing health and wellbeing for all, empowering individuals with vital genetic insights and enabling healthcare providers to better detect, treat and prevent disease.

Global Genetic Testing (Equipment & Consumables) Market 2021-2025: Rising Approval of Advanced Genetic Testing Products and Increasing Affordability - ResearchAndMarkets.com

Friday, June 4, 2021 - 10:28am

The genetic testing market is poised to grow by $5.39 billion during 2021-2025, progressing at a CAGR of about 12%.

Key Points: 
  • The genetic testing market is poised to grow by $5.39 billion during 2021-2025, progressing at a CAGR of about 12%.
  • The market is driven by the rising prevalence of genetic diseases and disorders, rising approval of advanced genetic testing products, and increasing affordability due to reduction in the cost of genetic testing.
  • The report on the genetic testing market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • This study identifies the advancements in next-generation sequencing as one of the prime reasons driving the genetic testing market growth during the next few years.

Avellino Launches AvaGen Nationwide as First Genetic Test to Quantify Keratoconus Risk and Presence of Corneal Dystrophies

Wednesday, June 2, 2021 - 12:30pm

Avellino Lab USA, Inc. (Avellino) today announced full nationwide availability in the U.S. of AvaGen, The Genetic Eye Test, as the first genetic test that helps determine a patients risk of keratoconus and the presence of other corneal dystrophies.

Key Points: 
  • Avellino Lab USA, Inc. (Avellino) today announced full nationwide availability in the U.S. of AvaGen, The Genetic Eye Test, as the first genetic test that helps determine a patients risk of keratoconus and the presence of other corneal dystrophies.
  • View the full release here: https://www.businesswire.com/news/home/20210602005304/en/
    AvaGen is the first genetic test that helps determine a patients risk of keratoconus and the presence of other corneal dystrophies.
  • The AvaGen genetic test examines 75 keratoconus-related genes and more than 2,000 variants of those genes to develop an actionable keratoconus genetic risk score.
  • As certain ethnicities have a higher prevalence of this eye condition1, the AvaGen test also factors this information into its results.

Myriad Genetics Completes the Sale of Myriad myPath® Melanoma, LLC, Laboratory to Castle Biosciences

Tuesday, June 1, 2021 - 12:05pm

SALT LAKE CITY, June 01, 2021 (GLOBE NEWSWIRE) -- On May 28, 2021, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, completed the sale of its wholly-owned subsidiary, Myriad myPath, LLC, which owns the laboratory that offers the myPath Melanoma test, to Castle Biosciences, Inc for $32.5 million in cash.

Key Points: 
  • SALT LAKE CITY, June 01, 2021 (GLOBE NEWSWIRE) -- On May 28, 2021, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, completed the sale of its wholly-owned subsidiary, Myriad myPath, LLC, which owns the laboratory that offers the myPath Melanoma test, to Castle Biosciences, Inc for $32.5 million in cash.
  • Myriad Genetics, is a leading genetic testing and precision medicine company dedicated to advancing health and wellbeing for all, empowering individuals with vital genetic insights and enabling healthcare providers to better detect, treat and prevent disease.
  • Myriad discovers and commercializes genetic tests that determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where genetic testing can significantly improve patient care and lower healthcare costs.
  • Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries.

Genomenon and Nostos Genomics Partner to Accelerate Rare Genetic Disease Diagnoses

Tuesday, June 1, 2021 - 5:00am

Mastermind connects patient genetic data with relevant evidence from scientific literature - an essential component of precision medicine for cancer and genetic disease.

Key Points: 
  • Mastermind connects patient genetic data with relevant evidence from scientific literature - an essential component of precision medicine for cancer and genetic disease.
  • Nostos Genomics' AION platform enhances genetic variant interpretation for clinical genetic testing by leveraging AI and functional genomics.
  • "We're excited to partner with Nostos Genomics to put the most comprehensive and up-to-date genomic research in the hands of geneticists and researchers to accelerate rare disease diagnosis," said Mike Klein, CEO of Genomenon.
  • Nostos Genomics is a company engaged in the AI-driven deciphering of genetic diseases, translating genetic information into impactful clinical interventions.

Germline genetic testing can benefit all cancer patients as a routine practice in cancer care

Tuesday, May 25, 2021 - 12:30pm

A separate study of prostate cancer patients confirmed similar findings in other cancer types that limiting testing deprives patients and clinicians of actionable information.

Key Points: 
  • A separate study of prostate cancer patients confirmed similar findings in other cancer types that limiting testing deprives patients and clinicians of actionable information.
  • In a review of two independent datasets, including commercially insured and Medicare Advantage enrollees, only 3% (n=1,675) of the 55,595 colorectal cancer patients received germline genetic testing, despite medical policy recommending germline genetic testing for all colorectal cancer patients (consistent with the INTERCEPT colorectal cancer study ).
  • These data presented at ASCO highlight the need for oncologists to embrace germline genetic testing as routine practice for all cancer patients," said Robert Nussbaum, M.D., chief medical officer at Invitae.
  • Invitae also provides patients direct access to genetic counselors, helping to integrate routine genetic testing into patient care with GIA, a HIPAA-compliant chatbot.